EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit
Attention to all investors in Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024, and July 24, 2024! The Rosen Law Firm, a trusted global investor rights law firm, wants to remind you of the crucial deadline of December 13, 2024, to become a lead plaintiff in the upcoming securities fraud lawsuit.
If you’re one of those who acquired securities during this class period, you might be eligible for compensation through a contingency fee arrangement, without any out-of-pocket fees. You can join the class action by visiting the provided link or reaching out to Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more details. It’s important to act before December 13, 2024, if you wish to be a lead plaintiff in this case.
Why trust Rosen Law Firm? We urge investors to choose experienced counsel with a proven track record in leading such cases. Unlike some other firms, the Rosen Law Firm specializes in securities class actions and shareholder derivative litigation. With significant achievements in recovering millions of dollars for investors, including record settlements, we are committed to fighting for your rights.
In this particular lawsuit, it’s alleged that during the Class Period, Edwards’ statements about its expected revenue for fiscal year 2024, especially regarding the growth of its core product, Transcatheter Aortic Valve Replacement (“TAVR”), were misleading. The lawsuit claims that investors suffered damages when the true details were revealed.
Remember, no class has been certified yet, so you’re not represented by counsel until you choose one. You have the option to remain an absent class member, but by taking an active role, you may have the opportunity to participate in any potential future recovery.
For more updates, follow us on LinkedIn and stay informed about the latest developments in this case.
